BrainKey
-87%
est. 2Y upside i
Brain Longevity
Rank
#1087
Sector
Digital Health, AI, Neurotechnology
Est. Liquidity
~5Y
Data Quality
Data: MediumThis equity opportunity presents a high-risk, moderate-upside profile, driven by BrainKey's innovative AI neurotechnology in a rapidly expanding market, but significantly constrained by its early stage, limited disclosed funding, and the formidable threat of dominant incumbents and regulatory complexities.
Last updated: February 16, 2026
BrainKey successfully secures significant follow-on funding, achieves medical device qualification, and rapidly expands market adoption through its differentiated multimodal AI platform, leading to a high-value acquisition by a major tech or healthcare company.
BrainKey continues to grow revenue steadily, maintains its Microsoft partnership, and makes progress on regulatory fronts, but faces ongoing funding challenges or slower-than-expected market penetration, resulting in a modest increase in valuation over two years without a clear exit.
BrainKey struggles to raise additional capital, faces increased competition from well-funded incumbents or direct competitors, encounters significant regulatory roadblocks, or fails to achieve widespread adoption, leading to a substantial loss of equity value or company failure.
Community
Valuation Sentiment
Our model estimates -87% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.